David Woodhouse, NGM Bio CEO

NGM tabled its NASH pro­gram in 2021 af­ter a key tri­al fail­ure. Now it’s re­port­ing suc­cess in a sec­ond study

Bay Area biotech NGM Bio­phar­ma­ceu­ti­cals re­port­ed Thurs­day af­ter­noon that its drug can­di­date for non-al­co­holic steato­hep­ati­tis, or NASH, im­proved re­sults on a liv­er bio­mark­er blood test in pa­tients with the most se­vere form of the dis­ease.

But the re­sults come af­ter NGM Bio de­cid­ed in 2021 against run­ning a piv­otal tri­al for the drug af­ter it failed a mid-stage tri­al in NASH pa­tients with less ad­vanced forms of the dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.